- Abstract
- Core Tip
- Full Article (PDF)
- Full Article with Cover (PDF)
- Full Article (XML)
- Full Article (HTML)
- Audio
- PubMed Central
- PubMed
- CrossRef
- Google Scholar
- Similar Articles (6013)
- Timeline of Article Publication (0)
- Authors Evaluation (1)
- Article Quality Tracking (0)
- Reference Citation Analysis (0)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3005)
All Articles published online
|
Publishing Process of This Article
|
Aug 6, 2024 (publication date) through Jul 18, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Park KH, Yoo JJ, Kim SG, Kim YS. Fatal intratumoral hemorrhage in a patient with hepatocellular carcinoma following successful treatment with atezolizumab/bevacizumab: A case report. World J Clin Cases 2024; 12(22): 5177-5183 [PMID: 39109046 DOI: 10.12998/wjcc.v12.i22.5177] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v12/i22/5177.htm |
| Number | Citing Articles |
| 1 |
Kazuhiro Tada, Shohei Yoshiya, Takaaki Mori, Ryoichi Narita, Kentaro Iwaki, Sota Nakamura, Yasunari Yamada, Hajime Takaki, Yo-ichi Yamashita, Kengo Fukuzawa. Tumor Rupture in a Patient with Recurrent Hepatocellular Carcinoma Following Atezolizumab plus Bevacizumab: A Case Report. Surgical Case Reports 2025; 11(1): n/a doi: 10.70352/scrj.cr.25-0331
|
| 2 |
|
| 3 |
Zhihong Chen, Junwei Zhang, Lei Zhang, Yaoge Liu, Ting Zhang, Xinting Sang, Yiyao Xu, Xin Lu. Evaluation of immune checkpoint inhibitor-associated hepatotoxic adverse events: A pharmacovigilance analysis based on the FAERS database. International Journal of Immunopathology and Pharmacology 2025; 39 doi: 10.1177/03946320251343943
|
| 4 |
Mina Tharwat, Ahmed Tawheed, Mohamed El-Kassas. Atezolizumab and bevacizumab combination in advanced hepatocellular carcinoma patients: The imperative for safety assessment studies. World Journal of Clinical Cases 2025; 13(9): 99043 doi: 10.12998/wjcc.v13.i9.99043
|